Organization: GlaxoSmithKline

Why Canada needs a national vaccine strategy

The private sector has little appetite for manufacturing small-volume, niche vaccines for pandemic viruses. That’s why any primary manufacturing facility for vaccines like COVID-19 need to be federally owned and operated.

Feds invest $887 million to ensure reliable vaccine supply for COVID-19, other pandemics

The federal government’s investment of $887 million make Canada self-sufficient in manufacturing vaccines against COVID-19 and future pandemics, say medical and other experts. Along with Canadian-led vaccine development, Ottawa is investing in a network of small-scale vaccine manufacturing facilities that together will be able to produce enough vaccine for Canada’s population during pandemics.

CATALIS welcomes new partners

The CATALIS Quebec Clinical Trials initiative has announced new public partners and industry funding as it moves closer to its goal of doubling private sector investment in the province’s early stage clinical trials (ESCT) and providing patients early access to innovative healthcare.

GSK forges novel R&D partnerships with CDRD

GlaxoSmithKline (GSK) has entered into a two-part R&D collaboration with the Centre for Drug Research and Development (CDRD) and its commercial arm CDRD Ventures Inc (CVI). The novel agreement will see GSK support early-stage projects through CDRD via the GSK-CDRD Innovation Fund. These projects will engage academic investigators at CDRD’s affiliated institutions or hospital-based research…

GSK launches $50-million Canadian VC fund

GlaxoSmithKline (GSK) has launched a $50-million venture capital fund to invest in early-stage, breakthrough research emanating from Canadian life sciences research institutions and start-up companies. The fund will be managed by SR One, GSK’s venture capital arm, which will assess opportunities in research from academic and health institutions, translational research centres and early-stage firms. Since…

SGC launches third phase with $49.9 million in funding

The Toronto-based Structural Genomics Consortium (SGC) has received $48.9 million to launch its third four-year phase. The funding is 30% less than in previous phases due primarily to the closure of the SGC laboratory at Karolinska Institutet in suburban Stockholm last June. The funding — 45% of which comes from commercial entities — will support…

GSK endows research chair at Univ of Manitoba

GlaxoSmithKline (GSK) is contributing $1 million to the Univ of Manitoba to establish an endowment for a research chair in the immunobiology of infectious disease. The funds will be used to establish the chair and recruit a top researcher as chairholder. The GSK endowment is part of the company’s $22-million initiative — Pathfinders Fund for…

Structural Genomics Consortium funding announced

Complete funding for the second phase of the Structural Genomics Consortium has been announced, with 13 partners (including three pharmaceutical firms) providing more than $105 million. The consortium — led by Dr Aled Edwards at the Univ of Toronto with three nodes in Toronto, the Univ of Oxford and the Karolinska Institutet — is dedicated…